Log in to save to my catalogue

RB loss in resistant EGFR mutant lung adenocarcinomas that transform to small-cell lung cancer

RB loss in resistant EGFR mutant lung adenocarcinomas that transform to small-cell lung cancer

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4357281

RB loss in resistant EGFR mutant lung adenocarcinomas that transform to small-cell lung cancer

About this item

Full title

RB loss in resistant EGFR mutant lung adenocarcinomas that transform to small-cell lung cancer

Publisher

London: Nature Publishing Group UK

Journal title

Nature communications, 2015-03, Vol.6 (1), p.6377-6377, Article 6377

Language

English

Formats

Publication information

Publisher

London: Nature Publishing Group UK

Subjects

Subjects and topics

More information

Scope and Contents

Contents

Tyrosine kinase inhibitors are effective treatments for non-small-cell lung cancers (NSCLCs) with
epidermal growth factor receptor
(
EGFR
) mutations. However, relapse typically occurs after an average of 1 year of continuous treatment. A fundamental histological transformation from NSCLC to small-cell lung cancer (SCLC) is observed in...

Alternative Titles

Full title

RB loss in resistant EGFR mutant lung adenocarcinomas that transform to small-cell lung cancer

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4357281

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4357281

Other Identifiers

ISSN

2041-1723

E-ISSN

2041-1723

DOI

10.1038/ncomms7377

How to access this item